Efficacy and Outcome with Felodipine in Heart failure - VHEFT-III


Felodipine vs. placebo in congestive heart failure


Felodipine when added to standard therapy for congestive heart failure including digoxin, diuretic and vasodilators (angiotensin converting enzyme inhibitors) would decrease mortality and be safely tolerated.

Study Design

Study Design:

Female: 0

Primary Endpoints:

Not detailed

Secondary Endpoints:

Not detailed

Drug/Procedures Used:


Principal Findings:

Felodipine significantly reduced blood pressure and, at 3 months, increased ejection fraction but did not improve exercise tolerance, quality of life, or the need for hospitalization.

During long-term follow-up, favorable effects on ejection fraction and atrial peptide did not persist, but felodipine prevented worsening exercise tolerance and quality of life.

All cause mortality no different between groups (13.8% felodipine, 12.8% placebo).

Felodipine appeared well tolerated.


These results suggest that outcome with regard to mortality were almost identical for Felodipine and placebo. The study had insufficient statistical power to detect a lack of adverse mortality effect. The drug appears to be safe but not clearly efficacious in patients with heart failure.


1. Am J Cardiol 1996;77:1078-82. Rationale and design
2. Circulation 1997;96:856-63. Final results

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: Exercise Tolerance, Felodipine, Follow-Up Studies, Digoxin, Diuretics, Blood Pressure, Vasodilator Agents, Calcium Channel Blockers, Oligopeptides, Quality of Life, Heart Failure

< Back to Listings